Table 3.

Treatment-related adverse events

	Anti-PD-1-exposed group (n=67)		Anti-PD-1-naive group (n=166)
	All grade, No. (%)	Grade 3 or 4, No. (%)	All grade, No. (%)	Grade 3 or 4, No. (%)
Leukocytopenia	42 (62.7)	18 (26.9)	125 (75.3)	38 (22.9)
Neutropenia	45 (67.2)	24 (35.8)	122 (73.5)	66 (39.8)
Anaemia	32 (47.8)	3 (4.5)	96 (57.8)	5 (3.0)
Thrombocytopenia	12 (17.9)	2 (3.0)	30 (18.1)	6 (3.6)
Febrile neutropenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatigue	13 (19.4)	0 (0.0)	34 (20.5)	0 (0.0)
Decreased appetite	25 (37.3)	0 (0.0)	62 (37.3)	0 (0.0)
Nausea	10 (14.9)	0 (0.0)	24 (14.5)	0 (0.0)
Vomiting	3 (4.5)	0 (0)	4 (2.4)	0 (0.0)
Diarrhoea	10 (14.9)	0 (0.0)	18 (10.8)	0 (0.0)
Stomatitis	9 (13.4)	0 (0.0)	5 (3.0)	0 (0.0)
Peripheral sensory neuropathy	27 (40.3)	0 (0.0)	77 (46.4)	0 (0.0)
Arthralgia/myalgia	5 (7.5)	0 (0.0)	5 (3.0)	0 (0.0)
Peripheral oedema	9 (13.4)	0 (0.0)	25 (15.1)	0 (0.0)
Epistaxis	4 (6.0)	0 (0.0)	8 (4.8)	0 (0.0)
Gastric haemorrhage	0 (0.0)	0 (0.0)	3 (1.8)	0 (0.0)
Hypertension	11 (16.4)	0 (0.0)	29 (17.5)	0 (0.0)
Proteinuria	13 (19.4)	0 (0.0)	25 (15.1)	0 (0.0)
Hypophysitis	1 (1.5)	1 (1.5)	0 (0.0)	0 (0.0)
Type 1 diabetes mellitus	1 (1.5)	1 (1.5)	0 (0.0)	0 (0.0)